Is rusfertide FDA-approved, and what does the research show?

What is rusfertide?

Rusfertide is a synthetic peptide that mimics hepcidin ². Hepcidin is the body's master iron-regulating hormone, and it decides how much iron is available for making red blood cells ¹. The label calls rusfertide "a synthetic cyclic peptide," a ring-shaped chain of amino acids, supplied as a powder for injection ².

It is approved for one disease. Polycythemia vera, PV for short, is a chronic condition in which the bone marrow makes too many red blood cells ⁵. The trial papers class it as a myeloproliferative neoplasm, the medical term for a disorder in which the marrow overproduces blood cells ¹, ⁹.

Is rusfertide FDA-approved?

Yes. Rusfertide is approved by FDA as the prescription medicine Mimrylo, with initial U.S. approval in 2026 ². FDA's approval letter, signed August 28, 2026, approves Takeda's new drug application, NDA 220605, "for the treatment of erythrocytosis in adults with polycythemia vera (PV)" ⁴. Erythrocytosis means too many red blood cells in the blood ⁵. Drugs@FDA lists five strengths of Mimrylo, all with marketing status "Prescription," as of November 9, 2026, the date of its data ³.

That is the label's one use ². It says safety and effectiveness in children have not been established ². The letter records that the product has an orphan drug designation for this use ⁴. FDA grants that designation to a drug "to prevent, diagnose or treat a rare disease or condition" ¹⁰. The route to the medicine is a licensed clinician's prescription ².

The approval came with a condition. FDA required Takeda to run a long-term safety study of trial participants with at least three years of follow-up, with a final report due in June 2029 ⁴. The letter also reminds Takeda of two commitments ⁴. One is to complete VERIFY, with completion scheduled for August 2028 ⁴. The other is to complete study PTG-300-21, which the letter names as THRIVE, "an ongoing multicenter, open-label, phase 3 trial," scheduled for January 2027 ⁴, ¹¹.

See the FDA status of every peptide, updated weekly.

How does rusfertide work?

The label says rusfertide "blocks the iron transporter ferroportin," the protein that lets iron out of cells into the blood ². With ferroportin blocked, less iron reaches the bone marrow, fewer red blood cells are made, and the hematocrit falls ². Hematocrit is the share of the blood made up of red blood cells, and treatment of PV aims to keep it under 45 percent ⁵.

The disease and its usual treatment both run on iron. Many people with PV have blood removed, a procedure called phlebotomy, to lower the red cell count, and each phlebotomy also takes iron out of the body ⁵. Rusfertide limits iron, so the trials asked whether it could hold the hematocrit below 45 percent without phlebotomy ⁵. In VERIFY, mean ferritin, a measure of stored iron, rose from 21 to 124 micrograms per liter by week 32 in the rusfertide arm ². This account of the mechanism is the label's and the trial papers', for an approved drug, from studies in people with PV ¹, ², ⁶.

What does the research show?

The evidence is at the top tier: FDA approval on a randomized, placebo-controlled phase 3 trial, the large final stage of testing before approval ², ⁴. Three phase 2 studies, the smaller stage before it, and a study in healthy volunteers came before it ¹, ⁹, ⁷, ⁸.

Studied in people against placebo: VERIFY, published online in October 2026, randomized 293 adults with PV who still needed frequent phlebotomy on their usual treatment ², ⁶. Entry required at least 3 phlebotomies in the previous 28 weeks or 5 in the previous year ². At randomization, 44.7 percent were on phlebotomy alone, and the rest also took a drug that lowers blood counts ². That drug was hydroxyurea in 38.9 percent, interferon in 13.3 percent, ruxolitinib in 2.4 percent, and a combination in 0.6 percent ².

They were assigned by chance to rusfertide or placebo, an inactive injection, on top of that treatment for 32 weeks, 147 against 146 ², ⁶. The trial was double-blind, meaning neither patients nor doctors knew who received which ⁶. The mean age was 57, 27 percent were women, and 89.4 percent were White ².

The primary outcome was a response, meaning no need for phlebotomy between weeks 20 and 32 by set hematocrit thresholds ², ⁶. It was reached by 113 of 147 (76.9 percent) on rusfertide and 48 of 146 (32.9 percent) on placebo ². That is a difference of 43.8 percentage points, with a 95 percent confidence interval, the range the true difference most likely lies in, of 33.5 to 54.2 ². Phlebotomies over the 32 weeks averaged 0.53 on rusfertide against 1.82 on placebo ². Hematocrit was held below 45 percent through week 32, one higher reading allowed, in 92 (62.6 percent) on rusfertide against 21 (14.4 percent) on placebo ².

On a standard fatigue score, rusfertide patients improved by 1.79 points while placebo patients worsened by 0.19, a difference of 1.98 points with a confidence interval of 0.25 to 3.71 ². The registry record lists 134 of 147 on rusfertide and 141 of 146 on placebo completing the 32 weeks ⁵. After week 32, placebo patients crossed over to rusfertide, and the trial's extension runs to 2028 ², ⁵. The label reports that mean hematocrit rose on placebo, stayed near or below its starting level on rusfertide, and fell "rapidly" once placebo patients switched ². Protagonist Therapeutics sponsored VERIFY ⁵.

Studied in people, phase 2: REVIVE, published in February 2024, enrolled 70 patients with phlebotomy-dependent PV, meaning they still needed regular blood removal ¹. Its first part was a 28-week dose-finding period with no comparison group ¹. Phlebotomies fell from an estimated 8.7 per year before treatment to 0.6 per year during it, and the mean maximum hematocrit fell from 50.0 to 44.5 percent ¹. Then 59 patients were randomized to continue rusfertide or switch to placebo for 12 weeks, 30 against 29 ¹. A response, meaning hematocrit control with no phlebotomy and completion of the regimen, occurred in 60 percent on rusfertide and 17 percent on placebo ¹.

Studied in people, open-label: a phase 2 study published online in October 2025 gave rusfertide to 20 patients with PV and a hematocrit above 48 percent ⁹. Open-label means every patient knew they received the drug ⁹. By week 8, 17 (85 percent) had a hematocrit below 45 percent, at a median of 4.9 weeks after the first dose, and none had a phlebotomy during treatment ⁹. Thirteen (65 percent) completed 52 weeks and 7 stopped ⁹. The study had no placebo arm ⁹.

Beyond PV: an open-label phase 2 trial published online in October 2023 treated 16 adults with HFE-related hereditary hemochromatosis ⁷. That is an inherited iron-overload disorder, named for the hereditary hemochromatosis protein, which is also managed by phlebotomy ⁷. Over 24 weeks, phlebotomies averaged 0.06 per patient against 2.31 in the 24 weeks before the trial, and 15 of 16 needed none ⁷. Rusfertide is not approved for hemochromatosis ³, ².

In 18 healthy volunteers enrolled for five weekly doses, 15 of whom completed the study, serum iron, transferrin saturation, hemoglobin and hematocrit all fell ⁸. Transferrin saturation is the share of the blood's iron-carrying protein loaded with iron, and hemoglobin is the oxygen-carrying protein of red blood cells ⁸. That fall is the drug's mechanism acting in people with no disease ⁸.

None of the sources cited here studies rusfertide for weight, muscle, energy, endurance or general health. The published placebo-controlled data run to 32 weeks ².

What are the side effects?

Injection-site reactions lead. In VERIFY's 32-week randomized period, 145 patients took rusfertide and 146 took placebo ². Injection-site reactions were reported by 56 percent on rusfertide against 33 percent on placebo, and anemia by 16 percent against 4.1 percent ². Thrombocytosis, a high count of platelets, the blood cells that form clots, was reported by 8 percent against 0.7 percent, and shortness of breath by 8 percent against 1.4 percent ².

Among all 285 patients exposed to rusfertide in the trial, the injection-site reactions were most often redness, itching, pain and swelling ². Two were grade 3, the severe step on the standard scale, and two patients stopped treatment because of them ².

Platelets are the warning the label puts first. Within 4 weeks of starting, platelet counts rose by an average of 31 percent; 36 percent of patients exceeded 600 billion per liter and 6 percent exceeded 1,000 billion ². Counts generally leveled off by week 8, and 1 percent of patients stopped treatment because of them ². The label tells clinicians: "After initiating MIMRYLO and during dose modifications, monitor CBC every 2 to 4 weeks or as clinically indicated," CBC being a complete blood count ². Dose reductions for an adverse reaction occurred in 30 patients (11 percent), 28 of them for anemia, and one patient had a serious adverse reaction of anemia ².

The registry record lists serious adverse events in 5 of 145 on rusfertide and 7 of 146 on placebo during the randomized period ⁵. Each serious term was a single case, and there were no deaths in either arm ⁵.

In REVIVE, grade 3 adverse events occurred in 13 percent of patients over both parts, and no patient had a grade 4 or 5 event, the two steps above it ¹. In the open-label phase 2 study, 17 of 20 patients (85 percent) had a treatment-emergent adverse event, most of grade 1 or 2 ⁹. In the hemochromatosis trial, one patient was diagnosed with pancreatic cancer 21 days after the first dose, judged pre-existing and unrelated to treatment ⁷.

FDA's label lists no contraindications, and its warnings are new or worsening thrombocytosis, injection-site reactions, and embryo-fetal toxicity ². On the last, it says "based on animal data, MIMRYLO can cause fetal harm" ². It adds that "pregnancy testing is recommended for females of reproductive potential prior to treatment," and to "use an effective method of contraception during treatment with MIMRYLO and for at least 30 days after the final dose" ². It tells clinicians to "advise patients not to breastfeed during treatment with MIMRYLO and for 30 days after the final treatment," because of "the potential for serious adverse reactions in the breastfed child, including impaired iron absorption" ².

Antibodies against the drug developed in 34 percent of VERIFY patients, and 12 percent of those cross-reacted with the body's own hepcidin ². The label found "no apparent correlation" between the antibodies and the drug's effect or safety ².

What the trials cannot yet settle is written into the approval. FDA's letter says only a clinical trial can "assess a signal of serious risk of thrombocytosis" ⁴. It must also identify any unexpected serious risk of thromboembolic events, which are blood clots, or of transformation to myelofibrosis or acute myeloid leukemia ⁴, two other bone marrow diseases. The same study must track the JAK2 allele burden and the use of cytoreductive therapy ⁴, the drugs that lower blood cell counts.

In sport

Rusfertide is not named on the 2026 Prohibited List of WADA, the World Anti-Doping Agency, and neither is hepcidin ¹². The list's section S2.1 covers "erythropoietins (EPO) and agents affecting erythropoiesis," the making of red blood cells ¹². None of S2.1's five named groups is a hepcidin mimetic ¹². S2.1's list is open ("Including, but not limited to"), and it does not say whether it reaches rusfertide ¹².

What JumpstartMD offers

JumpstartMD does not prescribe rusfertide. Our peptide library covers it so you have the facts on its FDA status and the evidence, current as of November 10, 2026.

Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.

Share your details and a JumpstartMD team member will reach out when we open.

Disclaimer

Compounded medications are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed. A licensed clinician decides after an evaluation whether a peptide is appropriate for you, and not every patient will qualify.